salicylic acid has been researched along with Migraine Disorders in 45 studies
Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).
Migraine Disorders: A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
| Excerpt | Relevance | Reference |
|---|---|---|
| " No adverse events were reported." | 3.01 | Effectiveness and safety of scalp acupuncture for treating migraine: A systematic review and meta-analysis. ( Heo, I; Hwang, EH; Hwang, MS; Kim, CY; Park, SY; Shin, BC, 2023) |
| "A pain visual analogue scale (VAS) and migraine therapy assessment questionnaire (MTAQ) were completed before treatment, after 6 and 18 sections of treatment, and 1 month after completion of therapy." | 2.79 | Efficacy of Yamamoto new scalp acupuncture versus Traditional Chinese acupuncture for migraine treatment. ( Fathimoghadam, F; Mohseni, M; Rezvani, M; Yaraghi, A, 2014) |
| "Migraine is a disorder that is prevalent worldwide." | 1.72 | Efficacy of scalp acupuncture for migraine: A protocol for systematic review and meta-analysis. ( Heo, I; Hwang, EH; Hwang, MS; Kim, CY; Park, SY; Shin, BC, 2022) |
| "We also examined effects due to migraine severity, gender, scalp-region and task (eyes-closed and eyes-open)." | 1.48 | Resting cranial and upper cervical muscle activity is increased in patients with migraine. ( Bakhshayesh, H; Fenton, N; Grummett, TS; Janani, AS; Lewis, TW; Pope, KJ; Watson, DH; Whitham, EM; Willoughby, JO, 2018) |
| "In some patients the pain of migraine originates in the extracranial cranial arteries." | 1.46 | A method for determining when the superficial scalp arteries are the source of migraine pain. ( Shevel, E, 2017) |
| "Clinical features of migraine, anxiety, and depression (Hospital Anxiety and Depression Scale, HADS) were collected." | 1.46 | Differences in Topographical Pressure Pain Sensitivity Maps of the Scalp Between Patients With Migraine and Healthy Controls. ( Arendt-Nielsen, L; Barón, J; Fernández-de-Las-Peñas, C; Guerrero, ÁL; Madeleine, P; Palacios-Ceña, M; Ruiz, M, 2017) |
| "Linear morphea en coup de sabre (ECDS) is a form of localized scleroderma that predominantly affects the pediatric population, with a median age of 10 years at presentation." | 1.40 | Headaches as a presenting symptom of linear morphea en coup de sabre. ( Gilmore, ES; Mathes, EF; Moon, A; Paller, AS; Polcari, I, 2014) |
| "During a migraine attack, of the 51 patients examined, 45 (88." | 1.36 | Painful scalp arteries in migraine. ( Cianchetti, C; Ledda, MG; Madeddu, F; Serci, MC, 2010) |
| "Advances in the understanding of migraine trigger points have pointed to entrapment of peripheral nerves in the head and neck as a cause of this debilitating condition." | 1.36 | The anatomy of the greater occipital nerve: Part II. Compression point topography. ( Becker, S; Ducic, I; Guyuron, B; Hamawy, AH; Hatef, DA; Janis, JE; Reece, EM, 2010) |
| "Medical treatment for certain chronic headache syndromes such as hemicrania continua (HC), chronic migraine (CM) or chronic cluster headache (CCH) is challenging and in many cases does not lead to sufficient pain relief or is limited by severe side effects." | 1.36 | [Subcutaneous peripheral stimulation of the greater occipital nerve for the treatment of chronic headache syndromes]. ( Rasche, D; Tronnier, V, 2010) |
| "However, migraine symptoms in some patients continue after this procedure." | 1.36 | Neurovascular compression of the greater occipital nerve: implications for migraine headaches. ( Guyuron, B; Hatef, DA; Janis, JE; McCluskey, PD; Reece, EM; Schaub, TA, 2010) |
| "The gradual development of cutaneous allodynia during the course of a migraine attack is commonly detected by quantitative sensory testing (QST) in migraineurs seeking secondary and tertiary medical help." | 1.33 | Can allodynic migraine patients be identified interictally using a questionnaire? ( Ashkenazi, A; Burstein, R; Jakubowski, M; Silberstein, S, 2005) |
| "Although migraine is a neurovascular disorder, both scalp tenderness and referred pain have been observed in migraine patients." | 1.33 | Trigger point evaluation in migraine patients: an indication of peripheral sensitization linked to migraine predisposition? ( Calandre, EP; García-Leiva, JM; Hidalgo, J; Rico-Villademoros, F, 2006) |
| "But patients with migraine had a reduced habituation, which probably reflects an abnormal excitability of the cortical areas involved in pain processing." | 1.32 | Reduced habituation to experimental pain in migraine patients: a CO(2) laser evoked potential study. ( Cruccu, G; de Tommaso, M; Di Trapani, G; Guido, M; Iannetti, GD; Le Pera, D; Libro, G; Puca, F; Restuccia, D; Tonali, P; Truini, A; Valeriani, M, 2003) |
| "A total of 157 (53." | 1.32 | Clinical recognition of allodynia in migraine. ( Kailasam, J; Mathew, NT; Seifert, T, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (31.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (24.44) | 29.6817 |
| 2010's | 18 (40.00) | 24.3611 |
| 2020's | 2 (4.44) | 2.80 |
| Authors | Studies |
|---|---|
| Smith, M | 1 |
| Jerusalem, F | 1 |
| Rhyner, K | 1 |
| Isler, H | 1 |
| Kim, CY | 2 |
| Hwang, EH | 2 |
| Heo, I | 2 |
| Park, SY | 2 |
| Shin, BC | 2 |
| Hwang, MS | 2 |
| Shevel, E | 2 |
| Tang, Y | 1 |
| Kang, J | 1 |
| Zhang, Y | 1 |
| Zhang, X | 1 |
| Janani, AS | 1 |
| Pope, KJ | 1 |
| Fenton, N | 1 |
| Grummett, TS | 1 |
| Bakhshayesh, H | 1 |
| Lewis, TW | 1 |
| Watson, DH | 1 |
| Whitham, EM | 1 |
| Willoughby, JO | 1 |
| Lee, M | 1 |
| Brown, M | 1 |
| Chepla, K | 1 |
| Okada, H | 1 |
| Gatherwright, J | 1 |
| Totonchi, A | 1 |
| Alleyne, B | 2 |
| Zwiebel, S | 2 |
| Kurlander, D | 1 |
| Guyuron, B | 6 |
| Rezvani, M | 1 |
| Yaraghi, A | 1 |
| Mohseni, M | 1 |
| Fathimoghadam, F | 1 |
| Del Fiacco, M | 1 |
| Quartu, M | 1 |
| Boi, M | 1 |
| Serra, MP | 1 |
| Melis, T | 1 |
| Boccaletti, R | 1 |
| Cianchetti, C | 6 |
| Silberstein, SD | 1 |
| Polcari, I | 1 |
| Moon, A | 1 |
| Mathes, EF | 1 |
| Gilmore, ES | 1 |
| Paller, AS | 1 |
| Cohen, SP | 1 |
| Peterlin, BL | 1 |
| Fulton, L | 1 |
| Neely, ET | 1 |
| Kurihara, C | 1 |
| Gupta, A | 1 |
| Mali, J | 1 |
| Fu, DC | 1 |
| Jacobs, MB | 1 |
| Plunkett, AR | 1 |
| Verdun, AJ | 1 |
| Stojanovic, MP | 1 |
| Hanling, S | 1 |
| Constantinescu, O | 1 |
| White, RL | 1 |
| McLean, BC | 1 |
| Pasquina, PF | 1 |
| Zhao, Z | 1 |
| Barón, J | 1 |
| Ruiz, M | 1 |
| Palacios-Ceña, M | 1 |
| Madeleine, P | 1 |
| Guerrero, ÁL | 1 |
| Arendt-Nielsen, L | 1 |
| Fernández-de-Las-Peñas, C | 1 |
| Hmaidan, Y | 3 |
| Finco, G | 1 |
| Ledda, MG | 2 |
| Franzini, A | 1 |
| Messina, G | 1 |
| Leone, M | 1 |
| Broggi, G | 1 |
| Serci, MC | 1 |
| Madeddu, F | 1 |
| Janis, JE | 4 |
| Hatef, DA | 2 |
| Ducic, I | 1 |
| Reece, EM | 2 |
| Hamawy, AH | 1 |
| Becker, S | 1 |
| Tronnier, V | 1 |
| Rasche, D | 1 |
| McCluskey, PD | 1 |
| Schaub, TA | 1 |
| Seo, BF | 1 |
| Jung, SN | 1 |
| Sohn, WI | 1 |
| Kwon, H | 1 |
| Caviggioli, F | 2 |
| Giannasi, S | 1 |
| Vinci, V | 1 |
| Cornegliani, G | 1 |
| Levi, D | 1 |
| Gaetani, P | 1 |
| Chim, H | 1 |
| Okada, HC | 1 |
| Brown, MS | 1 |
| Liu, MT | 1 |
| SICUTERI, F | 1 |
| Valeriani, M | 1 |
| de Tommaso, M | 1 |
| Restuccia, D | 1 |
| Le Pera, D | 1 |
| Guido, M | 1 |
| Iannetti, GD | 1 |
| Libro, G | 1 |
| Truini, A | 1 |
| Di Trapani, G | 1 |
| Puca, F | 1 |
| Tonali, P | 1 |
| Cruccu, G | 1 |
| Mosser, SW | 1 |
| Rohrich, RJ | 1 |
| Mathew, NT | 1 |
| Kailasam, J | 1 |
| Seifert, T | 1 |
| Dash, KS | 1 |
| Jakubowski, M | 1 |
| Silberstein, S | 1 |
| Ashkenazi, A | 1 |
| Burstein, R | 1 |
| Calandre, EP | 1 |
| Hidalgo, J | 1 |
| García-Leiva, JM | 1 |
| Rico-Villademoros, F | 1 |
| Lance, JW | 4 |
| Anthony, M | 2 |
| Hinterberger, H | 1 |
| Kudrow, L | 1 |
| Drummond, PD | 3 |
| Arthur, GP | 1 |
| Spierings, LH | 1 |
| Thomas, AL | 1 |
| Elkind, AH | 1 |
| Dalessio, DJ | 1 |
| Wood, EH | 1 |
| Friedman, AP | 1 |
| Holmes, LW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Acute Headache Treatment in Pregnancy: Improvement in Pain Scores With Occipital Nerve Block vs PO Acetaminophen With Caffeine A Randomized Controlled Trial[NCT03951649] | Phase 4 | 62 participants (Actual) | Interventional | 2020-02-10 | Completed | ||
| Greater Occipital and Supraorbital Nerve Blockade For The Preventive Treatment of Migraine[NCT03435185] | 103 participants (Actual) | Interventional | 2014-09-01 | Completed | |||
| Comparison of Heated vs. Pulsed Radiofrequency Treatment of the Genicular Nerves for Osteoarthritis Knee Pain[NCT04379895] | 60 participants (Anticipated) | Interventional | 2020-06-30 | Not yet recruiting | |||
| A Comparison of Pain Control AND Quality of Life Improvement Between Occipital Nerve Block And Occipital Nerve Radiofrequency Ablation: A Double-Blind Single Center Prospective Study[NCT04124458] | 70 participants (Anticipated) | Interventional | 2023-01-02 | Not yet recruiting | |||
| Pulsed vs Continuous Radiofrequency Neurotomy for Cervical Facet Joint Mediated Pain: a Single-blind Randomized Controlled Clinical Trial[NCT04124445] | 88 participants (Anticipated) | Interventional | 2020-02-10 | Recruiting | |||
| Randomized, Double-blind, Comparative-effectiveness Study Comparing Corticosteroid Injections to Pulsed Radiofrequency for Occipital Neuralgia[NCT01670825] | 81 participants (Actual) | Interventional | 2012-08-31 | Completed | |||
| Greater Occipital Nerve Pulsed Radiofrequency for the Treatment of Combined Migraine and Cervicogenic Headache (New Approach): Randomized Clinical Trial[NCT06121037] | 60 participants (Actual) | Interventional | 2022-01-01 | Completed | |||
| DO SOFT TISSUE TECHNIQUES HAVE A POSITIVE EFFECT ON DISABILITY AND QUALITY OF LIFE IN MIGRAINE SUFFERERS?: A Randomized Controlled Trial[NCT02446275] | 30 participants (Actual) | Interventional | 2014-01-31 | Completed | |||
| Effects of Myofascial Trigger Points Therapy in Migraine.[NCT05646160] | 100 participants (Anticipated) | Interventional | 2018-01-15 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT03951649)
Timeframe: 7 days
| Intervention | days (Median) |
|---|---|
| Occipital Nerve Block | 6 |
| Oral Acetaminophen/Caffeine Group | 1 |
(NCT03951649)
Timeframe: 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 9 |
| Oral Acetaminophen/Caffeine Group | 4 |
(NCT03951649)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 7 |
| Oral Acetaminophen/Caffeine Group | 2 |
Other: Pain at injection site (NCT03951649)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 0 |
| Oral Acetaminophen/Caffeine Group | 2 |
(NCT03951649)
Timeframe: 7 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 0 |
| Oral Acetaminophen/Caffeine Group | 0 |
(NCT03951649)
Timeframe: 4 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 9 |
| Oral Acetaminophen/Caffeine Group | 14 |
(NCT03951649)
Timeframe: 5 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 4 |
| Oral Acetaminophen/Caffeine Group | 2 |
Emergency department for treatment of headache since treatment asked at 28 day follow up (NCT03951649)
Timeframe: 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 5 |
| Oral Acetaminophen/Caffeine Group | 1 |
(NCT03951649)
Timeframe: 120 min
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 5 |
| Oral Acetaminophen/Caffeine Group | 5 |
Based on guidelines from the International Headache Society the primary outcome is the portion of women who experience resolution of headache or improvement of headache to mild range (VRS ≤ 3) at 2 hours following treatment with Occipital nerve block as compared to acetaminophen/caffeine cocktail. (NCT03951649)
Timeframe: 60-300 min
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 20 |
| Oral Acetaminophen/Caffeine Group | 16 |
"Visual/verbal Rating Score (VRS). VRS is used to assess pain in patients. With 0 representing no pain at all and 10 representing worst possible pain.~Total Minimum score=0 Total Maximum score=10~Higher values represent worse pain. If VRS=0, then the headache pain is considered resolved." (NCT03951649)
Timeframe: 60 min
| Intervention | score on a scale (Median) |
|---|---|
| Occipital Nerve Block | 6 |
| Oral Acetaminophen/Caffeine Group | 3 |
"Visual/verbal Rating Score (VRS). VRS is used to assess pain in patients. With 0 representing no pain at all and 10 representing worst possible pain.~Total Minimum score=0 Total Maximum score=10~Higher values represent worse pain. If VRS=0, then the headache pain is considered resolved." (NCT03951649)
Timeframe: 180min
| Intervention | score on a scale (Median) |
|---|---|
| Occipital Nerve Block | 6 |
| Oral Acetaminophen/Caffeine Group | 4 |
"Visual/verbal Rating Score (VRS). VRS is used to assess pain in patients. With 0 representing no pain at all and 10 representing worst possible pain.~Total Minimum score=0 Total Maximum score=10~Higher values represent worse pain. If VRS=0, then the headache pain is considered resolved." (NCT03951649)
Timeframe: 2 hrs
| Intervention | score on a scale (Median) |
|---|---|
| Occipital Nerve Block | 6.0 |
| Oral Acetaminophen/Caffeine Group | 6.5 |
Number of headache days in a month. Scores from both months were averaged. Minimum=0 Maximum=30. Lower scores mean a better outcome. (NCT03435185)
Timeframe: Patients were followed up from baseline to 2 months after first injection.
| Intervention | score on a scale (Mean) |
|---|---|
| Blockade Group | 5.3 |
| Placebo Group | 7.5 |
Mean visual analog scale (VAS) scores. Scores from both months were avareged. Minimum=0 Maximum=10. Lower scores mean a better outcome (NCT03435185)
Timeframe: Patients were followed up for 2 months from baseline after first injection.
| Intervention | score on a scale (Mean) |
|---|---|
| Blockade Group | 5.5 |
| Placebo Group | 7.4 |
This outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 2 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 2.495 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 3.694 |
This outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 3.791 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 4.441 |
The change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 4.312 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 4.765 |
The change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 3.068 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 3.738 |
This outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 2 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 3.392 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 4.220 |
This outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 4.000 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 4.694 |
This outcome measures the change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 6.761 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 7.556 |
This outcome measures the change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 3.678 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 4.410 |
This outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 2 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 5.540 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 6.650 |
This outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 6.522 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 7.417 |
This outcome measures the change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 6.761 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 7.556 |
This outcome measures the change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 6.583 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 6.825 |
This outcome will measure the participant's perceived improvement in sleep using the Athens Insomnia Scale. Scores in this scale can range from 0 to 24. 0 being the best possible outcome and 24 being the worst possible outcome. A score greater than or equal to 6 indicates a presence of insomnia. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 9.539 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 9.069 |
This outcome will measure the participant's perceived improvement in sleep using the Athens Insomnia Scale. Scores in this scale can range from 0 to 24. 0 being the best possible outcome and 24 being the worst possible outcome. A score greater than or equal to 6 indicates a presence of insomnia. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 9.256 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 9.431 |
This outcome will measure the participant's perceived improvement in sleep using the Athens Insomnia Scale. Scores in this scale can range from 0 to 24. 0 being the best possible outcome and 24 being the worst possible outcome. A score greater than or equal to 6 indicates a presence of insomnia. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 10.025 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 8.132 |
This outcome will measure the change in severity of depression using the Beck's Depression Inventory. Scores in this inventory can range from 0 to 63. 0 being the best possible outcome and 63 being the worst possible outcome. A score between 14 and 19 indicates mild depression and a score greater than or equal 29 indicates severe depression. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 11.333 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 11.972 |
This outcome will measure the change in severity of depression using the Beck's Depression Inventory. Scores in this inventory can range from 0 to 63. 0 being the best possible outcome and 63 being the worst possible outcome. A score between 14 and 19 indicates mild depression and a score greater than or equal 29 indicates severe depression. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 12.590 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 12.250 |
This outcome will measure the change in severity of depression using the Beck's Depression Inventory. Scores in this inventory can range from 0 to 63. 0 being the best possible outcome and 63 being the worst possible outcome. A score between 14 and 19 indicates mild depression and a score greater than or equal 29 indicates severe depression. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 12.775 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 10.842 |
This outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 2 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 4.726 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 5.846 |
This outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 5.850 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 7.149 |
This outcome measures the change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 6.705 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 7.541 |
The change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 5.354 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 6.064 |
This outcome measures what the patient feels they cannot do because headaches. This outcome is measured using the Headache Impact Test. Scores in this test range from range from 36 to 78, with higher scores indicating greater negative impact. A score of less than 50 indicates minimal impact, while a score greater than or equal to 60 indicates headaches are severely impacting one's life. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 59.718 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 60.556 |
This outcome measures what the patient feels they cannot do because headaches. This outcome is measured using the Headache Impact Test. Scores in this test range from range from 36 to 78, with higher scores indicating greater negative impact. A score of less than 50 indicates minimal impact, while a score greater than or equal to 60 indicates headaches are severely impacting one's life. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 59.641 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 61.389 |
This outcome measures what the patient feels they cannot do because headaches. This outcome is measured using the Headache Impact Test. Scores in this test range from range from 36 to 78, with higher scores indicating greater negative impact. A score of less than 50 indicates minimal impact, while a score greater than or equal to 60 indicates headaches are severely impacting one's life. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 60.087 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 59.553 |
This outcome will measure the number of days the patient has severe migraine headaches in the week (7 days) prior to the 3 month follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 2.087 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 2.263 |
This outcome will measure the number of days the patient has severe migraine headaches in the week (7 days) prior to the 6 month follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 2.044 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 2.368 |
This outcome will measure the number of days the patient has severe migraine headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 1.708 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 1.810 |
This outcome will measure the number of days the patient has severe occipital neuralgia headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: 3 months
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 1.846 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 1.919 |
This outcome will measure the number of days the patient has severe occipital neuralgia headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 2.128 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 2.162 |
This outcome will measure the number of days the patient has severe occipital neuralgia headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 1.436 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 1.436 |
3 reviews available for salicylic acid and Migraine Disorders
| Article | Year |
|---|---|
Effectiveness and safety of scalp acupuncture for treating migraine: A systematic review and meta-analysis.
Topics: Acupuncture Therapy; Headache; Humans; Medicine, East Asian Traditional; Migraine Disorders; Scalp | 2023 |
Influence of greater occipital nerve block on pain severity in migraine patients: A systematic review and meta-analysis.
Topics: Anesthetics, Local; Humans; Migraine Disorders; Nerve Block; Pain Measurement; Scalp; Treatment Outc | 2017 |
Influence of greater occipital nerve block on pain severity in migraine patients: A systematic review and meta-analysis.
Topics: Anesthetics, Local; Humans; Migraine Disorders; Nerve Block; Pain Measurement; Scalp; Treatment Outc | 2017 |
Influence of greater occipital nerve block on pain severity in migraine patients: A systematic review and meta-analysis.
Topics: Anesthetics, Local; Humans; Migraine Disorders; Nerve Block; Pain Measurement; Scalp; Treatment Outc | 2017 |
Influence of greater occipital nerve block on pain severity in migraine patients: A systematic review and meta-analysis.
Topics: Anesthetics, Local; Humans; Migraine Disorders; Nerve Block; Pain Measurement; Scalp; Treatment Outc | 2017 |
The role of the neurovascular scalp structures in migraine.
Topics: Humans; Migraine Disorders; Nociceptors; Pain; Scalp | 2012 |
4 trials available for salicylic acid and Migraine Disorders
38 other studies available for salicylic acid and Migraine Disorders
| Article | Year |
|---|---|
Salicylate prophylaxis in migraine.
Topics: Adolescent; Adult; Aged; Aspirin; Female; Humans; Male; Middle Aged; Migraine Disorders; Platelet Ag | 1984 |
Efficacy of scalp acupuncture for migraine: A protocol for systematic review and meta-analysis.
Topics: Acupuncture Therapy; Humans; Meta-Analysis as Topic; Migraine Disorders; Research Design; Review Lit | 2022 |
A method for determining when the superficial scalp arteries are the source of migraine pain.
Topics: Arteries; Blood Pressure; Headache; Humans; Migraine Disorders; Pain; Physical Examination; Scalp; T | 2017 |
Resting cranial and upper cervical muscle activity is increased in patients with migraine.
Topics: Adult; Electroencephalography; Electromyography; Female; Humans; Male; Middle Aged; Migraine Disorde | 2018 |
An anatomical study of the lesser occipital nerve and its potential compression points: implications for surgical treatment of migraine headaches.
Topics: Aged; Aged, 80 and over; Anatomic Landmarks; Cadaver; Cervical Vertebrae; Decompression, Surgical; H | 2013 |
TRPV1, CGRP and SP in scalp arteries of patients suffering from chronic migraine.
Topics: Adult; Aged; Arteries; Calcitonin Gene-Related Peptide; Female; Humans; Male; Middle Aged; Migraine | 2015 |
TRPV1, CGRP and SP in scalp arteries of patients suffering from chronic migraine. Some like it hot! Chronic migraine increases TRPV1 receptors in the scalp.
Topics: Arteries; Calcitonin Gene-Related Peptide; Female; Humans; Male; Migraine Disorders; Scalp; Substanc | 2015 |
Headaches as a presenting symptom of linear morphea en coup de sabre.
Topics: Adolescent; Biopsy; Brain; Child; Diagnosis, Differential; Drug Therapy, Combination; Female; Headac | 2014 |
Differences in Topographical Pressure Pain Sensitivity Maps of the Scalp Between Patients With Migraine and Healthy Controls.
Topics: Adult; Anxiety; Depression; Female; Functional Laterality; Humans; Hyperalgesia; Male; Migraine Diso | 2017 |
Scalp periarterial saline efficacy in migraine and relation to exploding and imploding headache.
Topics: Adolescent; Adult; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Migraine Disorders; | 2009 |
Occipital nerve stimulation (ONS). Surgical technique and prevention of late electrode migration.
Topics: Adult; Cluster Headache; Electric Stimulation Therapy; Electrodes, Implanted; Female; Foreign-Body M | 2009 |
Painful scalp arteries in migraine.
Topics: Adolescent; Adult; Case-Control Studies; Child; Child, Preschool; Female; Humans; Infant; Male; Midd | 2010 |
The anatomy of the greater occipital nerve: Part II. Compression point topography.
Topics: Adult; Aged; Aged, 80 and over; Cadaver; Female; Humans; Male; Middle Aged; Migraine Disorders; Neck | 2010 |
[Subcutaneous peripheral stimulation of the greater occipital nerve for the treatment of chronic headache syndromes].
Topics: Adult; Cervical Vertebrae; Cluster Headache; Electric Stimulation Therapy; Electrodes, Implanted; Fe | 2010 |
Neurovascular compression of the greater occipital nerve: implications for migraine headaches.
Topics: Adult; Aged; Aged, 80 and over; Arteries; Female; Humans; Male; Middle Aged; Migraine Disorders; Nec | 2010 |
Lymph node compression of the lesser occipital nerve: a cause of migraine.
Topics: Humans; Hyperplasia; Lymph Nodes; Magnetic Resonance Imaging; Male; Middle Aged; Migraine Disorders; | 2011 |
Neurovascular compression of the greater occipital nerve: implications for migraine headaches.
Topics: Female; Humans; Male; Migraine Disorders; Neck Muscles; Nerve Compression Syndromes; Scalp; Spinal N | 2012 |
The auriculotemporal nerve in etiology of migraine headaches: compression points and anatomical variations.
Topics: Anatomic Landmarks; Face; Humans; Migraine Disorders; Nerve Compression Syndromes; Parotid Gland; Sc | 2012 |
MAST CELLS AND THEIR ACTIVE SUBSTANCES: THEIR ROLE IN THE PATHOGENESIS OF MIGRAINE.
Topics: Benzaldehydes; Biochemical Phenomena; Biochemistry; Bradykinin; Catecholamines; Dogs; Drug Tolerance | 1963 |
Reduced habituation to experimental pain in migraine patients: a CO(2) laser evoked potential study.
Topics: Adult; Case-Control Studies; Cerebral Cortex; Evoked Potentials; Female; Habituation, Psychophysiolo | 2003 |
The anatomy of the greater occipital nerve: implications for the etiology of migraine headaches.
Topics: Humans; Migraine Disorders; Peripheral Nerves; Scalp | 2004 |
Clinical recognition of allodynia in migraine.
Topics: Adolescent; Adult; Aged; Arm; Female; Humans; Hyperalgesia; Male; Middle Aged; Migraine Disorders; P | 2004 |
The lesser and third occipital nerves and migraine headaches.
Topics: Botulinum Toxins, Type A; Dissection; Humans; Migraine Disorders; Neuromuscular Agents; Peripheral N | 2005 |
Can allodynic migraine patients be identified interictally using a questionnaire?
Topics: Adult; Afferent Pathways; Female; Humans; Hyperalgesia; Male; Migraine Disorders; Neurologic Examina | 2005 |
Trigger point evaluation in migraine patients: an indication of peripheral sensitization linked to migraine predisposition?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Case-Control Studies; Disease Susceptibility; Female; Hu | 2006 |
Trigger point evaluation in migraine patients: an indication of peripheral sensitization linked to migraine predisposition?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Case-Control Studies; Disease Susceptibility; Female; Hu | 2006 |
Trigger point evaluation in migraine patients: an indication of peripheral sensitization linked to migraine predisposition?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Case-Control Studies; Disease Susceptibility; Female; Hu | 2006 |
Trigger point evaluation in migraine patients: an indication of peripheral sensitization linked to migraine predisposition?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Case-Control Studies; Disease Susceptibility; Female; Hu | 2006 |
The control of cranial arteries by humoral mechanisms and its relation to the migraine syndrome.
Topics: Arteries; Humans; Migraine Disorders; Scalp; Serotonin | 1967 |
Paradoxical effects of frequent analgesic use.
Topics: Adult; Amitriptyline; Analgesics; Drug Tolerance; Female; Headache; Humans; Hypnotics and Sedatives; | 1982 |
Extracranial vascular reactivity in migraine and tension headache.
Topics: Adult; Ergotamine; Female; Headache; Humans; Male; Middle Aged; Migraine Disorders; Propranolol; Sca | 1981 |
Motion sickness and migraine: optokinetic stimulation increases scalp tenderness, pain sensitivity in the fingers and photophobia.
Topics: Adult; Female; Fingers; Humans; Middle Aged; Migraine Disorders; Motion Perception; Motion Sickness; | 2002 |
Migraine in adults.
Topics: Acute Disease; Adult; Cerebral Cortex; Ergotamine; Female; Humans; Male; Migraine Disorders; Scalp; | 1978 |
Craniovascular accompaniments of the vascular headache of the migraine type.
Topics: Blood Circulation; Face; Humans; Migraine Disorders; Scalp; Thermography; Vascular Headaches; Vasoco | 1979 |
Periodic migrainous neuralgia associated with an arteriovenous malformation.
Topics: Adult; Arteriovenous Malformations; Humans; Male; Migraine Disorders; Neuralgia; Scalp | 1975 |
Scalp tenderness and sensitivity to pain in migraine and tension headache.
Topics: Adult; Female; Headache; Humans; Male; Migraine Disorders; Pain; Pain Measurement; Pressure; Scalp; | 1987 |
Muscle contraction headache. Overview and update of a common affliction.
Topics: Diagnosis, Differential; Female; Headache; Humans; Male; Migraine Disorders; Muscle Contraction; Mus | 1987 |
A classification of headache.
Topics: Antidepressive Agents; Anxiety; Arteritis; Aspirin; Depression; Ergot Alkaloids; Facial Neuralgia; H | 1970 |
The pathophysiology and treatment of migraine.
Topics: Blood Platelets; Blood Vessels; Constriction; Cortical Spreading Depression; Dilatation; Ergot Alkal | 1974 |
Thermography in migraine.
Topics: Carotid Arteries; Face; Humans; Migraine Disorders; Regional Blood Flow; Scalp; Thermography | 1971 |
The effect of serotonin on cranial vessels and its significance in migraine.
Topics: Carotid Body; Cerebral Arteries; Humans; Migraine Disorders; Scalp; Serotonin; Skull; Vasoconstricto | 1968 |